Because HOMA-IR is a marker of insulin resistance based on hyperinsulinemia16, the direct inhibitory action of SELENOP on pancreatic insulin secretion could produce a seeming discrepancy between SELENOP and HOMA-IR in the current non-diabetic population. Here, INS is linked to Insulin resistance.